What Gabrilen Treats: Main Uses and Benefits

Gabrilen (Ketoprofen) is used across several therapeutic domains where relief from pain, inflammation, and fever is necessary to support symptomatic comfort and function.

---

Therapeutic Scope and Benefits

Gabrilen is commonly applied in conditions characterized by chronic, persistent inflammation—such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis—as well as acute painful episodes. The medication is considered relevant for soft tissue trauma like sprains and strains, inflammation of tendons or bursae, pain following dental surgery, and intense symptomatic manifestations like acute gout flares and primary dysmenorrhea. The medication may assist with maintaining a sense of stability and helps ease symptoms when they become difficult to tolerate.

A key purpose is providing supportive relief when symptoms interfere with routine activities, which contributes to improved comfort during these acute phases. This usage contributes to easing the overall symptom load, supporting patients during episodes of heightened discomfort across musculoskeletal and systemic symptoms, including the reduction of fever.

---

Quick Fact: Relief for Acute Discomfort
Target Symptoms	Pain, Swelling, Stiffness, Fever
Typical Contexts	Post-trauma, Post-operative, Acute Inflammatory Flares
Primary Benefit	Symptomatic relief, support for functional stability

Regulatory References

1. NIH LiverTox overview

Eligibility Map: Who can and cannot use Gabrilen — Official Regulatory Information

The official eligibility profile for Gabrilen (Ketoprofen) is defined by a series of absolute prohibitions and restrictions documented by government regulatory agencies.

---

Eligibility Status	Defined Populations/Conditions
Contraindicated	Patients with known hypersensitivity to ketoprofen or any NSAID, including a history of aspirin-induced asthma or urticaria [1.3]. Also, use is prohibited for treating peri-operative pain in the setting of CABG surgery and in the third trimester of pregnancy [1.5].
Not Established	Pediatric patients (under 18 years) for oral formulations; safety and effectiveness have not been formally established in this population [3.1].
Conditional Use	Patients with impaired renal or hepatic function must use Gabrilen with caution, often requiring dose reduction or careful monitoring due to potential for reduced drug clearance [3.5]. Older adults are at a greater risk for serious gastrointestinal and cardiovascular events and require close supervision [1.2].

---

Age and State Rules	Regulatory Statement
Pregnancy	Contraindicated in the third trimester. Avoid use from 20 weeks gestation [4.3].
Lactation	Not recommended as the potential for adverse effects in the infant is not fully established [4.1].

The regulatory structure emphasizes that active gastrointestinal disease (such as peptic ulcers) and a history of recent myocardial infarction also severely limit or prohibit use [3.2].

Gabrilen (Tiagabine) is subject to alterations in its blood concentration when co-administered with certain other medicinal products, primarily due to effects on drug metabolism.

Pharmacokinetic Interactions

Enzyme-Inducing Anti-epileptic Drugs (AEDs): Co-administration with hepatic enzyme-inducing AEDs, such as Phenytoin, Carbamazepine, Phenobarbital, and Primidone, enhances the metabolism of Tiagabine. This metabolic change can significantly reduce the plasma concentration of Tiagabine by a factor of 1.5 to 3. Patients taking these inducing agents may require Tiagabine doses in the upper range of the usual dose.

Non-Inducing AEDs: Tiagabine has a minor effect on the plasma concentration of Valproate, reducing it by approximately 10%. This effect is officially documented as not clinically important and does not require dose adjustment. Tiagabine does not significantly alter the concentration of other tested anti-epileptic agents, including Phenytoin, Carbamazepine, Phenobarbital, or Primidone.

Other Agents: The non-AED agent Cimetidine increases the bioavailability of Tiagabine by about 5%, an effect also considered not clinically important.

Herbal Product Restriction

St John's Wort (Hypericum perforatum): The use of Tiagabine with the herbal product St John's Wort is contra-indicated in regulatory documents. St John's Wort is a potent enzyme inducer that can decrease Tiagabine exposure, which may lead to a loss of efficacy.

The mechanism of action for Gabrilen (Ketoprofen) involves the pharmacodynamic modulation of eicosanoid signaling pathways through enzyme inhibition. Its primary mechanistic focus is the non-selective inhibition of Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This interaction is competitive and occurs at the active sites of both enzyme isoforms.

These COX enzymes normally catalyze the conversion of arachidonic acid into various biological mediators, including prostaglandins. By blocking this catalysis, Gabrilen suppresses a key early molecular step in the cascade. This leads directly to a reduction in the synthesis and local concentration of prostaglandins and other eicosanoids, which are critical lipid signaling molecules associated with nociceptor sensitization, vascular changes, and the central elevation of body temperature. The subsequent reduction of these mediators results in decreased pathway activation within targeted biological systems, leading to a dampening of elevated physiological responses associated with inflammation and fever. This pattern of physiological adjustment defines the drug's core pharmacologic effect.

How to Use Gabrilen (Ketoprofen): Administration Guidelines

Gabrilen, a brand name for the NSAID ketoprofen, is used according to labeling instructions. This section summarizes the instructions for administration and dosing.

---

Dosage Forms, Route, and Integrity

Entity	Instruction
Route of Administration	Oral (by mouth).
Capsule Integrity	Capsules must be swallowed whole. Do not crush, chew, or open.

---

Standard Dosing and Scheduling

Dosing Type	Instruction
Immediate-Release (IR)	Taken multiple times daily (e.g., every 6 to 8 hours). The standard single dose is typically 25 mg to 75 mg.
Extended-Release (ER)	Taken once daily. Standard dose is typically 200 mg.
Maximum Daily Limit	The total daily dose generally should not exceed 300 mg of the immediate-release form.

---

Administration Conditions and Adjustments

Gabrilen may be taken with food, milk, or an antacid to help reduce the possibility of stomach upset. It should be taken with a full glass of water.

Population-Specific Dosing Rules:

Labeling instructions include dose reductions for specific patient groups:

• Elderly Patients (age 75 and older): A reduced initial dosage is required due to potential changes in drug clearance.
• Impaired Renal or Hepatic Function: The dosage must be lowered, often to a maximum of 100 mg per day, for patients with moderate to severe impairment.

Missed Dose: If a dose is missed, it should be skipped if it is almost time for the next scheduled dose. Resume the regular schedule; do not double the dose.

Gabrilen: Recent Clinical Evidence

The clinical evidence for Gabrilen's active ingredient, Ketoprofen, includes Randomized Controlled Trials (RCTs) and systematic reviews that explored how symptoms change over time in adult patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Research examined outcomes related to physical discomfort, joint stiffness, and measures reflecting daily functioning or activity level. Findings describe patterns where the medicine's use was associated with specific measurements of change in symptoms when compared to placebo. Some meta-analyses also report on outcomes related to symptomatic pain when the medicine was evaluated against other nonsteroidal anti-inflammatory drugs (NSAIDs).

---

Research has explored the medicine's use in acute conditions associated with disruptive episodes, such as post-operative pain and primary dysmenorrhea. Ultra-short-term RCTs examined the time it took for patients to report initial pain changes and the overall outcomes related to pain over short observation periods. Findings describe group patterns related to the onset of change in reported discomfort, often noting a specific time frame when compared to a placebo. Separate clinical evidence confirms that the topical gel was studied for localized conditions like osteoarthritis of the knee, monitoring outcomes related to local pain and physical function over 6 to 12 weeks.

---

The majority of clinical studies designed to contribute to the evidence base for chronic conditions had limited follow-up durations, often lasting only a few weeks to a few months. Long-term effects are therefore not fully established based on the initial clinical trials alone. Research has focused mainly on adult patients; however, the regulatory evidence base often notes that the research and evaluation of outcomes for specific Gabrilen formulations in the pediatric population (children under 18) are not fully established for all use scenarios. Data for certain adult groups remain insufficient, and evidence quality varies across older studies. Findings describe group patterns, and research does not determine whether an individual will respond similarly to the patients observed in the studies.

Key Studies & References

1. Ketoprofen (LiverTox: Clinical and Research Information on Drug-Induced Liver Injury)
2. Summary of Product Characteristics (SmPC) / Labeling for Ketoprofen Hard Capsules (Representative Regulatory Document)

Common questions about Gabrilen (FAQ)

---

Q: What are the main conditions that Gabrilen is approved to treat?

Regulatory documents confirm the medicine is officially approved for managing pain related to specific chronic conditions, including rheumatoid arthritis (RA) and osteoarthritis (OA). It is also approved for treating the pain associated with primary dysmenorrhea and for general relief of mild to moderate pain.

---

Q: Are there different strengths or formulations of Gabrilen available?

Yes, regulatory documents confirm the medicine is manufactured in multiple forms to address different needs. These forms include immediate-release and extended-release capsules for oral use, a topical gel for application to the skin, and an injectable solution.

---

Q: How quickly should I expect Gabrilen to start working?

Studies indicate that for the immediate-release form, the medicine is rapidly absorbed into the body. Peak concentrations in the blood are generally reached within 30 minutes to two hours after taking a dose. This rapid absorption pattern is typically when the drug begins to exert its effects.

---

Q: What happens to Gabrilen in the body after it is taken?

According to pharmacokinetics information, the medicine is rapidly absorbed from the digestive tract and is then extensively metabolized (chemically changed) in the liver. Once metabolized, the resulting inactive compounds are primarily eliminated from the body through urine.

---

Q: Is Gabrilen a controlled substance?

No, the active ingredient in Gabrilen is not classified as a controlled substance by major regulatory agencies like the US Drug Enforcement Administration (DEA). The medicine is not associated with a known risk of dependency or physical addiction.

---

Q: Is Gabrilen safe to use long-term?

The official regulatory warnings indicate that the risk of serious adverse events, including those affecting the heart and blood vessels (cardiovascular thrombotic events) and the gastrointestinal system (bleeding or ulcers), may increase with the duration of use. Clinical studies designed to determine long-term effects often have limited follow-up periods.

---

Q: Does Gabrilen carry a Black Box Warning?

Yes, the medicine carries a Boxed Warning in its official labeling. This warning highlights the elevated risks of serious cardiovascular thrombotic events (such as heart attack and stroke) and severe gastrointestinal adverse events (like bleeding or perforation).

---

Q: What are the less common, but more serious, side effects associated with Gabrilen?

Serious adverse effects are highlighted in regulatory warnings. These include serious cardiovascular events which can be life-threatening, severe gastrointestinal issues like bleeding and perforation, serious skin reactions, and acute renal failure.

---

Q: Does Gabrilen typically cause weight gain or loss?

Both weight gain and weight loss are officially listed as reported adverse reactions in the medicine’s safety profile. The occurrence of these specific effects is documented in regulatory sources.

---

Q: Can Gabrilen affect sleep patterns?

Official documents confirm that side effects affecting the nervous system include trouble sleeping and sleeplessness, which is also referred to as insomnia. Drowsiness and dizziness are also noted as common side effects.

---

Q: Can taking Gabrilen cause issues with blurred vision?

Blurred vision is officially listed as a possible side effect of the medicine. Any changes to vision should be discussed with a healthcare provider.

---

Q: Is it possible for Gabrilen to affect blood pressure?

Yes, the official warnings state that the medicine can lead to the new onset of hypertension (high blood pressure) or the worsening of pre-existing hypertension. The official label indicates that blood pressure monitoring is necessary during treatment.

---

Q: What kind of monitoring (e.g., blood tests) might be needed while taking Gabrilen?

The official label indicates that laboratory monitoring is required, particularly for those on long-term treatment. This includes tests for kidney function (e.g., BUN, creatinine), liver function (e.g., transaminases), and full blood counts (CBC).

---

Q: What percentage of people experience the most common side effects of Gabrilen?

While the official product label does not state a single percentage, it often provides a table listing the specific incidence rates of adverse reactions observed in clinical trials. These rates are usually presented as a percentage for comparison against placebo groups.

---

Q: Can I use Gabrilen if I have a history of heart problems?

The official label notes that the medicine may increase blood pressure and can cause or worsen fluid retention and heart failure. It is strictly prohibited (contraindicated) for pain management right before or after coronary artery bypass graft (CABG) surgery.

---

Q: Is Gabrilen known to interact with common pain relievers like ibuprofen?

Official labeling indicates that co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) such as ibuprofen or naproxen, or with aspirin, is generally avoided due to the increased risk of serious side effects.

---

Q: Can I drink alcohol while I am using Gabrilen?

Regulatory warnings indicate that the concurrent use of alcohol may significantly increase the risk of serious gastrointestinal bleeding. The official label recommends that patients discuss alcohol consumption with their healthcare provider.

---

Q: Is there a list of common foods or supplements that interact with Gabrilen?

Official product information states that taking the medicine with food or milk may slow how quickly it is absorbed. The use of certain herbal supplements like St. John's Wort is also officially cautioned against or contraindicated, as it may interfere with the medicine's effectiveness.

---

Q: Can I drive a car while taking Gabrilen?

The official label states that due to the potential for dizziness, drowsiness, or blurred vision, patients should avoid driving or operating complex machinery until they know how the medicine affects them.

---

Q: Has Gabrilen been studied in diverse patient populations?

Official documents note specific populations where the research base is incomplete or where caution is required. For instance, the safety and effectiveness for pediatric patients (under 18) are generally not established. Dose adjustments are formally required for older adults and individuals with impaired kidney or liver function.

---

Q: What does the patient information leaflet say about stopping Gabrilen?

Official documentation indicates that stopping the medicine or changing the prescribed dosage should only be done after consulting with a healthcare provider. This is standard guidance to ensure safety and prevent adverse outcomes.

The storage and disposal of Gabrilen (Ketoprofen) must align with official regulatory requirements to ensure product stability and safety.

Storage Conditions

Gabrilen capsules must be stored at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F). The container must be kept tightly closed in its original package to protect the medicine from excessive heat, moisture, and direct light. The product should be kept from freezing and should not be refrigerated.

Child Safety and Disposal

Official labeling mandates that this medication be stored out of the sight and reach of children at all times. Unused or expired Gabrilen must be disposed of safely, preferably through a drug take-back program or as advised by a pharmacist, in accordance with local, national, and international regulations. The medication must not be flushed down a toilet or poured into a drain.